Kevin  Tan net worth and biography

Kevin Tan Biography and Net Worth

Mr. Tan is the Chief Financial Officer & Treasurer of Solid Biosciences and leads all financial functions, corporate communications and investor relations.

Mr. Tan has served as the Chief Financial Officer of Solid Biosciences since January 2023.

From September 2021 to November 2022, Mr. Tan was Chief Financial Officer at Selecta Biosciences Inc., a biopharmaceutical company. While there, he led all financial functions, business development, corporate communications, and investor relations. From May 2018 to September 2021, Mr. Tan held positions of increasing responsibility at Sarepta Therapeutics, Inc., a precision genetic medicine company. He was a key member of the Business Development team and ultimately served as Treasurer of the organization. Prior to Sarepta, Kevin had a long career in financial services most recently as Senior Portfolio Manager at CPP Investments, the national pension fund of Canada. Prior to CPP Investments, Kevin worked in capital markets roles at Macquarie Capital and Lehman Brothers and in Mergers & Acquisitions at UBS Investment Bank.

Mr. Tan received a Bachelors of Commerce from Queen’s University at Kingston, a Masters Degree in Engineering in Operations Research and Financial Engineering from Princeton University and an MBA from The University of Chicago Booth School of Business. Mr. Tan is a Chartered Financial Analyst.

What is Kevin Tan's net worth?

The estimated net worth of Kevin Tan is at least $146.75 thousand as of January 10th, 2025. Mr. Tan owns 24,789 shares of Solid Biosciences stock worth more than $146,751 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Tan may own. Additionally, Mr. Tan receives a salary of $607,180.00 as CFO at Solid Biosciences. Learn More about Kevin Tan's net worth.

How old is Kevin Tan?

Mr. Tan is currently 46 years old. There are 6 older executives and no younger executives at Solid Biosciences. The oldest executive at Solid Biosciences is Mr. Ian F. Smith A.C.A., C.P.A., Executive Chair, who is 58 years old. Learn More on Kevin Tan's age.

What is Kevin Tan's salary?

As the CFO of Solid Biosciences Inc., Mr. Tan earns $607,180.00 per year. There are 3 executives that earn more than Mr. Tan. The highest earning executive at Solid Biosciences is Mr. Alexander G. Cumbo, President, CEO & Director, who commands a salary of $918,550.00 per year. Learn More on Kevin Tan's salary.

How do I contact Kevin Tan?

The corporate mailing address for Mr. Tan and other Solid Biosciences executives is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. Solid Biosciences can also be reached via phone at (617) 337-4680 and via email at [email protected]. Learn More on Kevin Tan's contact information.

Has Kevin Tan been buying or selling shares of Solid Biosciences?

Kevin Tan has not been actively trading shares of Solid Biosciences over the course of the past ninety days. Most recently, Kevin Tan sold 4,073 shares of the business's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $3.89, for a transaction totalling $15,843.97. Following the completion of the sale, the chief financial officer now directly owns 24,789 shares of the company's stock, valued at $96,429.21. Learn More on Kevin Tan's trading history.

Who are Solid Biosciences' active insiders?

Solid Biosciences' insider roster includes Gabriel Brooks (Chief Medical Officer), Alexander Cumbo (President & CEO), Ilan Ganot (Co-Founder and Strategic Advisor to the CEO), Jessie Hanrahan (Chief Regulatory & Preclinical Operations Officer), Paul Herzich (CTO), David Howton (COO), Clare Kahn (Director), Carl Morris (Insider), and Kevin Tan (CFO). Learn More on Solid Biosciences' active insiders.

Are insiders buying or selling shares of Solid Biosciences?

During the last twelve months, Solid Biosciences insiders bought shares 1 times. They purchased a total of 1,860 shares worth more than $9,932.40. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 31,092 shares worth more than $155,239.01. The most recent insider tranaction occured on December, 3rd when COO David T Howton sold 4,932 shares worth more than $25,202.52. Insiders at Solid Biosciences own 1.9% of the company. Learn More about insider trades at Solid Biosciences.

Information on this page was last updated on 12/3/2025.

Kevin Tan Insider Trading History at Solid Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2025Sell4,073$3.89$15,843.9724,789View SEC Filing Icon  
1/9/2024Sell3,935$8.20$32,267.009,308View SEC Filing Icon  
See Full Table

Kevin Tan Buying and Selling Activity at Solid Biosciences

This chart shows Kevin Tan's buying and selling at Solid Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Solid Biosciences Company Overview

Solid Biosciences logo
Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Read More

Today's Range

Now: $5.92
Low: $5.36
High: $5.97

50 Day Range

MA: $5.34
Low: $3.93
High: $6.40

2 Week Range

Now: $5.92
Low: $2.41
High: $7.37

Volume

1,597,066 shs

Average Volume

1,045,629 shs

Market Capitalization

$461.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.97